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Abstract: 
Objective: Characterize long-term cranial nerve (CN) outcomes following sentinel lymph node biopsy 
(SLNB) based management for head and neck cutaneous melanoma (HNCM). 
Methods: Longitudinal review of HNCM patients undergoing SLNB from 1997-2007 
Results: 356 patients were identified, with mean age 53.5+/-19.0 years, mean Breslow depth 2.52+/-
1.87mm, and 4.9 years median follow-up. 105(29.4%) patients had SLNB mapping to the parotid basin. 
18 patients had positive parotid SLNs and underwent immediate parotidectomy/iCLND, with 6 
possessing positive parotid NSLNs. 52 of 356 (14.6%) patients developed delayed regional recurrences, 
including 20 total intraparotid recurrences: 5 following false negative (FN) parotid SLNB, 3 following 
prior immediate superficial parotidectomy, 2 following iCLND without parotidectomy, and the remaining 
12 parotid recurrences had negative extraparotid SLNBs. Parotid recurrences were multiple (4.9 mean 
recurrent nodes) and advanced (n=4 extracapsular extension), and all required salvage dissection 
including parotidectomy. Immediate parotidectomy/iCLND led to no permanent CN injuries. Delayed 
regional HNCM macrometastasis precipitated 16 total permanent CN injuries in 13 patients: 10 CN VII, 5 
CN XI, and 1 CN XII deficits. 50% (n=10) of parotid recurrences caused ≥1 permanent CN deficits. 
Conclusions: Regional HNCM macrometastases and salvage dissection confer marked CN injury risk, 
whereas early surgical intervention via SLNB+/-iCLND+/-immediate parotidectomy yielded no CN 
injuries. Further, superficial parotidectomy performed in parotid-mapping HNCM does not obviate 
delayed intraparotid recurrences, which increase risk of CN VII injury. Despite lack of a published disease 
specific survival advantage in melanoma, early disease control in cervical and parotid basins is 
paramount to minimize CN complications. 
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CN   Cranial nerve 
iCLND   Immediate completion lymph node dissection 
CLND   Completion lymph node dissection 
DFS   Disease free survival 
HNCM, H&N  Head and neck cutaneous melanoma, Head and neck 
MSLT   Multicenter Selective Lymphadenectomy Trial 
MSS   Melanoma specific survival 
NSLN   Non-sentinel lymph node 
OS   Overall survival 
SLNB, SLN  Sentinel lymph node biopsy, Sentinel Lymph Node 
FN   False negative 
 
Level of Evidence: 4 (retrospective case series) 
 
Introduction: 
The crucial importance of regional nodal metastasis for prognostication, disease recurrence, and 
survival in melanoma is well-supported with prospective data reflected by AJCC staging and NCCN 
treatment guidelines [1-5].  Sentinel lymph node biopsy (SLNB) is recommended for cN0 T2-T4 and 
select T1b melanomas, and until recently immediate completion lymph-node dissection (iCLND) was 
recommended following all positive SLNBs [2, 6-8]. The initial Multicenter Selective Lymphadenectomy 
Trial (MSLT-I) demonstrated that SLNB followed by iCLND among patients with regionally metastatic 
melanoma confers prolonged disease free survival (DFS) and melanoma specific survival (MSS) over 
observation [9-13]. SLNB+/-iCLND-based treatment was subsequently proven effective, safe, prognostic, 
and accurate for head and neck cutaneous melanoma (HNCM) [12]. 
Despite improved DFS over observation, failure of MSLT-II [7] and DeCOG-SLT [8] to establish 
overall survival (OS) and MSS benefits for iCLND over observation following positive SLNB has led 
opponents to argue that potential iCLND complications (predominantly truncal or extremity 
lymphedema) unquestionably outweigh its DFS benefits [7, 8]. Consequently, MSLT-II concluded that 
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iCLND is “unlikely to benefit” patients with positive non-sentinel lymph nodes (NSLN) [7], leading to 
dispute regarding the necessity and timing of CLND among patients with microscopically positive NSLNs 
[4, 5, 7].  
 Asserting that lymphedema is prohibitive to iCLND’s DFS benefits is problematic and 
questionably relevant to HNCM, as H&N lymphedema is not reported in MSLT-II and rarely encountered 
in large HNCM SLNB cohorts [7, 12, 14-19]. Rather, uncontrolled HNCM behaves more aggressively than 
other sites and enacts unique complications, namely cranial nerve (CN) and carotid injuries  [6, 12, 14, 
20, 21]. Conversely, SLNB+/-iCLND’s safety has been compellingly demonstrated in HNCM cohorts [12, 
14, 20-24]. Delayed excision of macroscopically positive NSLN’s may alternatively negate benefits of 
iCLND risk-avoidance by heightening complications and lengthening hospitalizations [25]. Specifically, 
intraparotid disease control is paramount in stage III HNCM, as nodal recurrence in an undissected deep 
parotid lobe is associated with a 42% CN VII injury risk [26, 27]. Challenges for surgeons and patients 
arising from salvage interventions and palliation of uncontrolled regional disease in HN malignancies 
[28] provide further support for iCLND. Locoregionally-advanced HNCM and/or associated cranial 
neuropathies may threaten function and quality of life years ahead of disease-specific mortality [28], 
lending DFS and regional disease control pivotal importance for HNCM. 
We evaluate CN outcomes following SLNB+/-CLND-based management for HNCM including FN 
SLNB and in-field recurrences following iCLND. Here, we test the hypothesis that regional HNCM 
recurrence and/or ensuing salvage dissection will lead to poorer CN outcomes. Finally, we evaluate the 
effects of parotidectomy-timing and -extent on recurrence-related CN injuries by comparing immediate 
superficial parotidectomy, intraparotid recurrences following FN SLNB, and published total 
parotidectomy rates [26, 29]. 
 
Materials and Methods: 
This study was conducted with University of Michigan Institutional Review Board approval. 
Longitudinal review was performed of the prospectively collected database of 356 HNCM patients who 
underwent WLE and SLNB+/-iCLND from 1997 to 2007 based on NCCN guidelines [27]. Following a 
positive SLNB, iCLND was recommended with consideration for adjuvant therapies.  Patients with 
negative SLNB were monitored clinically, and salvage dissection was recommended for treatable 
macroscopic recurrences [12]. Surgical techniques, lymphatic mapping and SLN localization techniques, 
and histopathologic analysis for this cohort are previously described [12]. Relevant patient data was 
collected including SLNB outcomes, basins dissected and NSLN-involvement during iCLND, patterns and 
characteristics of locoregional recurrence, extent of salvage dissection, and CN injury presence and 
severity. Data acquisition was performed via medical record review, patient telephone interview, 
communication with referring provider(s), and Social Security Death Index. CN outcomes and 
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recurrences were primary measures. Regional recurrence patterns, clinical follow-up, time-to-
recurrence, cause of death, and time-to-mortality were tabulated where applicable.  
Two distinct patient populations were examined in this study following post-SLNB regional 
recurrence: 1) false negative (FN) SLNB who sustained regional nodal basin recurrence and 2) patients 
with true positive SLNB who underwent iCLND but subsequently developed regional nodal basin 
recurrence. Both subsets were offered surgical therapy following regional recurrence when appropriate. 
Nodal observation +/- serial ultrasound was neither within this study’s treatment intent nor explicitly 
offered to patients following positive SLNB.  The term “delayed completion lymph node dissection” is 
reserved for reference to treatment strategies in which clinical observation was explicitly stated as an 
intended treatment regimen, such as after WLE in lieu of SLNB or following positive SLNB in lieu of iCLND 
[7, 30]. In this analysis, delayed regional lymph node dissection following FN SLNB or failed iCLND is 
termed “salvage dissection.”  
Results:  
Patient Demographics and Tumor Characteristics 
356 eligible HNCM patients underwent WLE/SLNB from 1997 to 2007 with mean age 53.5±19 
years, 26.6% female, and mean Breslow depth 2.52±1.87mm. Median follow-up was 4.9 years. A study 
population flow diagram including SLNB sites and histopathologic status, patterns of recurrence, and CN 
outcomes is shown in Figures 1A/1B. 
Regional recurrence: 
52 (14.6%) patients recurred regionally following SLNB+/-iCLND-based management, which 
translates to 85.4% long-term regional disease control. 73 of 75 (97.3%) patients with positive SLNB 
underwent iCLND, and 20 showcased positive NSLNs. 21 (28.8%) patients recurred following iCLND in 
regional HN basins (Levels I-VI, suboccipital, and/or parotid basin), including 10 patients with positive 
NSLN’s at the time of iCLND.  Ten patients with post-iCLND regional recurrences showcased nodal 
positivity during salvage dissection including eight nodal recurrences in previously dissected basins 
during iCLND. One patient recurred in a previously dissected external jugular basin but declined salvage 
dissection due to concurrent distant metastasis prior to suffering recurrence-related CN XI injury. 12.3% 
(n=9) of iCLND’s failed to achieve long-term regional nodal control among immediately dissected basins. 
SLNB+/-iCLND failed to identify melanoma-containing nodal basins in 20 (5.6%) total patients (18 FN 
SLNB and 2 nodal recurrences outside of basins dissected during iCLND). 
Parotid-mapping SLNB:  
105 patients (29.4%) had at least one parotid-mapping SLN. Primary sites with at least one 
parotid SLN were most frequently the ipsilateral ear (27%), cheek (15%), and temple (9%). Figure 2 
showcases primary site distribution for parotid-localizing SLNBs. Mean Breslow depth among parotid-
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mapping sites was 2.23±1.52mm. Mean 2.94 SLNs were extracted (median 2) from an average of two 
lymphatic basins. 
Positive Parotid Basin SLNB and Immediate Parotidectomy:  
Of 75 positive SLNB’s, 19 patients had positive intraparotid or periparotid SLNBs. In total 20 
patients underwent superficial parotidectomy as part of iCLND, including seven specimens containing 
positive intraparotid NSLNs.  
False Negative SLNB, Parotid False Negative SLNB:  
Of 18 total FN SLNBs, four patients had at least one negative intraparotid SLN and later 
sustained ipsilateral parotid bed macrometastasis. Additionally, one patient had a negative intraparotid 
SLN but positive jugulodigastric SLNs, prompting ipsilateral iCLND, including cervical levels I-V without 
parotidectomy. These five cumulative intraparotid FN SLNBs translate to a 5.8% intraparotid false 
omission rate (5 FN/(5 FN + 81 TN)).  
Intraparotid Recurrences, Salvage Parotidectomy  
Following SLNB+/-iCLND+/-superficial parotidectomy, twenty patients sustained delayed 
intraparotid recurrences. The majority (17/20) of patients with intraparotid recurrences had not 
previously undergone parotidectomy prior to the first parotid recurrence. Three patients suffered 
delayed intraparotid recurrences following immediate superficial parotidectomy, which translates to a 
15% recurrence rate after immediate superficial parotid dissection. Two of the immediate superficial 
parotidectomy specimens contained no additional intraparotid NSLNs, whereas one possessed a single 
intraparotid NSLN. 
All patients with delayed intraparotid recurrences underwent salvage dissection, at minimum 
including ipsilateral parotidectomy. Four patients’ nodal recurrences exhibited extracapsular extension, 
and salvage specimens for intraparotid recurrences contained 4.87 average total positive lymph nodes.  
CN Outcomes 
No CN injuries were noted following any combination of SLNB, immediate superficial 
parotidectomy, and/or iCLND. However, 13 patients (25.0%) with regional recurrences developed 16 
total permanent CN injuries. Recurrence-related CN outcomes included 10 CN VII deficits (3 complete- 
and 7 partial-distribution deficits), five CN XI/SCM deficits, and one CN XII deficit. Ten of sixteen CN 
deficits involved paresis resulting from neural dissection during salvage surgery, implying that nerve 
function was at least partially preserved in all salvage dissections in which nerve sacrifice was not 
oncologically required. The remaining six injuries arose from neural tumor invasion including two CN 
paresis and four CN paralyses with or without oncologically-mandated nerve sacrifice.  
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Among 18 total FN SLNB, seven (38.9%) developed permanent recurrence-related CN injuries 
with a mean time-to-CN-injury of 3.45±2.04 years. Moreover, six (28.6%) patients sustained recurrence-
related permanent CN injuries despite prior iCLND+/-superficial parotidectomy for SLN-positivity with 
3.11±2.71 years mean time-to-CN-injury.  
The large predominance of cumulative CN injuries (13 of 16) occurred secondary to delayed 
intraparotid recurrences. 10 of 20 (50%) delayed parotid recurrences developed permanent CN VII 
injuries. Further, three intraparotid recurrences yielded multiple cranial neuropathies. Recurrence-
related CN VII injuries were frequent among the few patients who recurred in a previously mapped 
and/or dissected parotid basin, including four of five (80%) FN parotid-mapping SLNB’s and two of three 
(66%) intraparotid recurrences following immediate superficial parotidectomy. 
A complete description of patients suffering permanent cranial neuropathies following regional 
HNCM recurrence is showcased in Table 1.  
Discussion: 
The current study affirms that HNCM management combining SLNB +/- iCLND (including 
immediate parotidectomy when indicated) is safe and highly efficacious with long-term follow-up. 
However, the few delayed regional HNCM recurrences following SLNB-guided management are often 
advanced with considerable morbidity, including substantial CN-injury-risk not seen with iCLND. 
Therefore, early regional disease control in HNCM is vital to minimize recurrence-related CN 
complications, particularly within the parotid basin. Further, at-risk parotid basins addressed with 
superficial parotidectomy alone remain susceptible to intraparotid recurrences, which imposes risk of 
potentially multiple CN injuries. Therefore, surgeons should consider total parotidectomy in at-risk 
parotid basin management. Overall, our 25% incidence of CN injury following delayed regional 
macrometastases after SLNB-guided management argues against the MSLT-II authors’ advocacy for 
delayed excision of post-observation regional recurrences [7]. Instead we contend that iCLND should be 
performed for at-risk basins whenever possible in HNCM. Furthermore, we assert that the risks of 
SLNB+/-iCLND for HNCM are not sufficient to forgo the DFS benefits and potential to improve CN 
outcomes, irrespective of iCLND’s effects on MSS.  
Despite persuasive evidence supporting early regional disease control among affected patients 
in landmark trials, opponents of iCLND posit that surgical toxicities in unaffected patients unequivocally 
outweigh iCLND’s DFS benefit, improved regional disease control, and added staging benefits [31]. 
Although a secondary endpoint, MSLT-II showcased improved DFS following iCLND compared to 
observation for SLN-positivity, including 69% fewer regional recurrences [7, 8]. A 2010 MSLT-I interim 
analysis also demonstrated increased complication frequency and severity following 
observation/delayed CLND compared to SLNB/iCLND with resultant lengthened post-operative 
hospitalizations [25]. Recognizing the majority of complications reported in MSLT-II (i.e. lymphedema) as 
“mild,” “transient,” and limited to the extremities [7, 32] renders the argument to forgo iCLND’s DFS 
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benefit [31] inapplicable to HNCM. HNCM’s well-established uniquely aggressive behavior is associated 
with historically poorer prognosis and higher mortality than other sites, poorly predictable lymphatic 
mapping and recurrence patterns, and a distinct complication profile [12, 14, 22, 26, 33-40]. Unlike the 
trunk and extremities, HNCM iCLND complications rarely include lymphedema due to watershed H&N 
lymphatic drainage [22]. We have previously reported only a single case of mild lymphedema following 
iCLND in this cohort, resolving spontaneously within 4 weeks [41]. Moreover, HNCM was historically 
viewed as sufficiently unique to evoke intense skepticism prior to SLNB’s widespread adoption [12-14, 
21, 22, 34, 35, 40, 42-51]. Likewise, our study suggests that MSLT-II’s conclusions similarly warrant 
intense scrutiny before abandoning H&N iCLND, which may increase CN injury frequency and severity 
[7].  Unfortunately, a sufficiently-powered prospective HNCM study examining the efficacy of SLNB with 
immediate NSLN excision versus observation is unlikely [6]. However, our study shows that SLNB-guided 
regional nodal management of cN0 HNCM is highly efficacious, evidenced by 85.4% regional disease 
control with 4.9 years of median follow-up. Additionally, while parotid dissection was historically viewed 
as technically challenging and potentially dangerous [23, 52], we demonstrate a low long-term 
intraparotid false omission rate of 5.8%, which favorably compares to prior studies [30, 35, 40, 46, 47, 
51-67] and is notably superior to the 6.4% long-term false omission rate for the entire study cohort [41]. 
The extent of regional surgical dissection in at-risk HN lymphatic basins represents another 
important question regarding DFS and resultant CN injury risk. Historically, two CN XI injuries in the 
Sunbelt Melanoma Trial provoked safety concerns regarding dissection near CN VII and CN XI  and 
reticence to perform SLNB in HNCM [14, 20, 22]. Subsequently, large exclusively HNCM cohorts in high-
volume cutaneous oncology centers have overwhelmingly demonstrated the safety of SLNB+/-iCLND in 
HNCM, without permanent CN or clinically significant vascular injuries despite over one-in-four HNCM 
SLNBs mapping to the parotid [12, 14, 20-24]. Our results reiterate the safety of SLNB (n=356) and iCLND 
(n=73) by showcasing zero SLNB- or iCLND-related permanent CN injuries. Our study also demonstrates 
that even with SLNB+/-iCLND’s high efficacy and safety that the expense of relatively few delayed 
regional recurrences in HNCM is potentially immense, with 25% (n= 13 of 52) of regional recurrences at 
all HNCM sites resulting in at least one permanent CN injury. Likewise, while limited by the sensitivity of 
SLNB and iCLND, our findings support early accurate diagnosis of micrometastases and swift surgical 
management of affected HNCM basins whenever possible. This is perhaps most apparent when 
examining the 33% (6/18) of FN SLNB’s of the H&N who developed permanent cranial neuropathies 
upon regional recurrence. Acknowledging that our study enrollment closed over 10 years ago, interval 
advances such as the development of SPECT/CT, growing expertise in SLNB for HNCM, and 
establishment of high-volume multidisciplinary cutaneous oncology centers may further improve 
already highly accurate, efficacious, and prognostic SLNB-guided therapy in HNCM [12, 20, 68-71]. These 
advances may translate to improved recurrence rates and thereby improved CN outcomes.  
  High-level surgical expertise in HNCM cultivated over the last 3 decades has begun to shift fear 
from surgical complications to fear of CN injury from insufficient nodal dissection by permitting 
recurrence in previously undissected or underdissected at-risk HN basins [26]. The risk of uncontrolled 
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locoregional disease arising from undissected at-risk NSLNs poses immense risks of cranial neuropathy 
and therefore poses risk to patient function, identity, and quality of life that are distinct from other 
primary sites and may occur independently of MSS [28]. Particularly, CN VII injury following intraparotid 
recurrence imposes an immense quality of life impairment. The recurrence rate of stage III melanoma 
following superficial parotidectomy has been reported at rates of 7%-13% [26, 72]. Conversely, null 
recurrence following total parotidectomy for HNCM has repeatedly been reported [26, 29] without a 
significant difference in surgical CN VII injury between primary superficial versus total parotidectomy 
[26, 27]. Notably, among 129 stage III HNCM patients with either macro- or micrometastatic parotid 
involvement, Wertz, et al reported superior recurrence rates and CN VII outcomes following total 
parotidectomy versus superficial parotidectomy in stage III HNCM, prompting the NCCN to endorse 
consideration of total parotidectomy for intraparotid stage III HNCM [26]. Among recurrences in 
previously undissected deep parotid lobes, there was a 42% risk of permanent CN VII injury [26]. In our 
cohort, three patients suffered delayed intraparotid recurrences after immediate superficial 
parotidectomy (15%), and an additional five sustained intraparotid recurrence after a FN parotid SLNB. 
Intraparotid recurrence following SLNB, regardless of histopathologic status, imparted CN VII injury risk. 
Specifically, macrometastatic recurrence in a previously undissected total parotid basin (n=4 of 5, 80%) 
following falsely negative SLNB and/or undissected deep parotid lobe (n=2 of 3, 66%) following 
immediate superficial parotidectomy accounted for a cumulative 50% (n=10 of 20) permanent CN VII 
injury rate among all parotid recurrences in this cohort. 
Moreover, in our small 13-patient subset with 16 cumulative permanent CN injuries, all 10 
injuries from neural dissection during salvage surgery maintained at least partially-preserved long-term 
nerve function. Alternatively, an increasing degree of motor neuropathy was cumulatively observed 
involving the six CN injuries arising from tumor invasion or oncologic nerve sacrifice in HNCM, including 
three total-distribution CN (VII or XI) paralyses and one upper division CN VII division paralysis. 
Therefore, while salvage surgery for regional HNCM macrometastases imposes its own CN injury risk, 
prompt surgical salvage in well-selected patients may facilitate fewer CN injuries with less severe motor 
dysfunction compared to uncontrolled disease progression. Delayed intraparotid recurrence was 
encountered in at least one instance in which parotid SLNB was negative whereas SLNB in other cervical 
basins was positive. In this case, iCLND was performed without immediate parotidectomy prior to 
intraparotid recurrence and CN VII injury. Therefore, SLN-positivity in any basin merits iCLND-
consideration encompassing all SLN-containing basins, including basins yielding only negative SLNs.  
Limitations of this study include the few patients on which conclusions have been based. 
Thankfully, SLNB-guided management’s long-term safety and fidelity at high-volume centers make both 
regional recurrences and associated CN injuries rare events. We argue that iCLND should be favored 
over observation in HNCM to potentially prevent even rare recurrence-related cranial neuropathies, 
given neck dissection’s excellent safety profile [41]. Conversely, no existing evidence supports clinical 
observation as sufficiently sensitive to prevent delayed CN injury as a presenting manifestation of 
recurrence. This study’s interventions precede recently-approved systemic molecularly-targeted and 
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immune therapeutics for stage III/IV melanoma, which promise to markedly enhance advanced HNCM 
outcomes. In addition to established DFS benefits and potential CN injury risk-avoidance, iCLND’s NSLN 
histopathologic data may allow adjuvant therapy risk-stratification [73-81]. High-risk NSLN-positive 
strata defined by iCLND may justify early systemic treatment (e.g. immunotherapy) in well-selected 
patients and perhaps avoid severe, potentially lethal toxicities (e.g. bowel perforation, hepatotoxicity, 
hypophysitis, pneumonitis, cardiac myositis, arrhythmias, etc.) [82] in low-risk patients. 
Conclusions: 
SLNB-guided HNCM management remains highly accurate and prognostic with excellent long 
term regional disease control, but even rare HNCM regional recurrences impart substantial CN injury 
risk. Conversely, SLNB +/- iCLND (including immediate parotidectomy when indicated) is safe, yielding no 
CN injuries. For intraparotid SLN-positivity, surgeons should consider deep parotid lobe dissection. For 
delayed macrometastatic HNCM recurrences, prompt salvage surgery for amenable recurrences may 
facilitate fewer CN injuries with less severe motor neuropathies. The high incidence of cranial 
neuropathy following regional HNCM recurrence argues in favor of iCLND following positive SLNB in 
attempt to gain early regional melanoma control. iCLND-mediated DFS and CN injury benefits likely 
endure in HNCM regardless of its influence on MSS. 
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Figure 1A and 1B. Study population flow diagrams sorted by SLNB mapping to parotid or non-parotid 
cervical basins, SLNB result, presence and location of regional recurrence if applicable, and presence of 
CN injury if applicable. Intraparotid recurrences are denoted by red text, and CN injuries are denoted by 
blue text. Key: HNCM, head and neck cutaneous melanoma; SLNB, sentinel lymph node biopsy; iCLND, 
immediate completion lymph node dissection; CN, cranial nerve; FN, False Negative. 
 
Figure 2: Head and Neck Melanoma Primary Sites with Sentinel Node Mapping to Parotid 
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Table 1: Summary of permanent cranial neuropathies following regional HNCM recurrence 
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Figure 1A and 1B. Study population flow diagrams sorted by SLNB mapping to parotid or non-parotid cervical basins, SLNB result, presence and location of 
regional recurrence if applicable, and presence of CN injury if applicable. Intraparotid recurrences are denoted by red text, and CN injuries are denoted by 
blue text. Key: HNCM, head and neck cutaneous melanoma; SLNB, sentinel lymph node biopsy; iCLND, immediate completion lymph node dissection; CN, 
cranial nerve; FN, False Negative. 
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